Physician profile
Roberto Carrasco
NPI 1740364652
$1,766.85
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $161 · 2021: $191 · 2022: $218 · 2023: $530 · 2024: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.28 | 2019-2023 | Lo Loestrin Fe |
| Novo Nordisk INC | $291.11 | 2019-2023 | Wegovy |
| Organon LLC | $216.42 | 2024 | |
| Allergan, INC. | $158.61 | 2019 | |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Pfizer INC. | $114.51 | 2022-2023 | |
| Abbott Laboratories | $85.88 | 2024 | Proclaim |
| Lilly USA, LLC | $57.29 | 2024 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $50.63 | 2019 | |
| Mayne Pharma Commercial LLC | $44.41 | 2023 | |
| Eisai INC. | $40.55 | 2019 | |
| Sumitomo Pharma America, INC. | $33.91 | 2023-2024 | Myfembree |
| Evofem Biosciences, INC. | $22.15 | 2022 | |
| Daiichi Sankyo INC. | $19.33 | 2022 | |
| Ethicon US, LLC | $18.06 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $13.90 | 2022 | |
| Therapeuticsmd, INC. | $12.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Carrasco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.